How can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy?

Area of Science:

• Oncology
• Pharmacology

Background:

• Metastatic renal cell carcinoma (mRCC) treatment historically relied on cytokine therapy (interferon, interleukin-2).
• Novel targeted agents (bevacizumab, sorafenib, sunitinib, temsirolimus) show efficacy in cytokine-refractory mRCC.
• Targeted agents are now standard first-line therapy for mRCC, often replacing or augmenting cytokines.

Purpose of the Study:

• To re-evaluate the role and optimal selection of second-line therapies for mRCC.
• To define strategies for maximizing patient benefit from available mRCC treatments.
• To assess the activity and tolerability of second-line agents in patients refractory to targeted therapy.

Main Methods:

• Review of available clinical trial data and therapeutic strategies for mRCC.
• Analysis of patient outcomes based on prior treatment with targeted agents.
• Consideration of drug mechanisms and pathway inhibition for sequential therapy.

Main Results:

• Patients refractory to one targeted agent may benefit from alternative agents targeting the same or different pathways.
• Optimal sequencing of therapies is essential given the limited number of available drugs.
• Defining active and tolerable second-line therapy is critical for overall treatment strategy.

Conclusions:

• Second-line therapy for mRCC requires careful consideration of prior treatments.
• Individualized therapeutic strategies are necessary to optimize outcomes in mRCC.
• Further definition of second-line treatment efficacy and tolerability is important for advancing mRCC care.